Key result
Anti-CarP antibodies linked to ~140% higher bone erosion prevalence in RA, independent of anti-CCP status.
Why the study?
Are anti-CarP antibodies independently associated with clinical and genetic features of rheumatoid arthritis in a Spanish cohort?
Observational (n=798)
No
Are anti-CarP antibodies independently associated with clinical and genetic features of rheumatoid arthritis in a Spanish cohort?
Odds Ratio: 2.4
p-value: p=2.0 x 10^-4
Anti-CarP antibodies are a reproducible, independent type of autoantibody in rheumatoid arthritis associated with bone erosions.
Anti-CarP antibodies may refine erosion risk stratification in RA beyond anti-CCP; hypothesis-generating and requires prospective validation before clinical adoption.
A large fraction of the patients with rheumatoid arthritis (RA) develop specific autoantibodies, which until recently were only of two types, rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). We aimed to replicate important findings about a recently described third type of specific autoantibodies, anti-carbamylated protein (anti-CarP) antibodies, because they have been described based only in the homemade ELISA from a single laboratory. Our study included 520 patients with established RA and 278 healthy controls of Spanish ancestry and it was done with an independently performed ELISA. The prevalence and pattern of environmental, clinical and genetic associations of the anti-CarP antibodies were similar to the previously described. Notably, the presence and titers of anti-CarP correlated with the presence and titers of ACPA, but the anti-CarP antibodies did not share the known genetic and exposure risk factors of the ACPA. In addition, anti-CarP antibodies were independently associated with a higher (10.5%) prevalence of bone erosions. The reproducibility of these characteristics across laboratories and European subpopulations, indicates the wide validity of the results and suggests that determination of anti-CarP antibodies could contribute to explain RA pathogenesis and identify clinically relevant patient subgroups.
No takes yet. Share an insight, caveat, or question.
Montes et al. (2016) conducted an observational in Rheumatoid arthritis (n=798). Anti-carbamylated protein (anti-CarP) antibodies vs. Anti-CarP negative status was evaluated on Presence of bone erosions (OR 2.4, p=2.0 x 10^-4). The presence of anti-carbamylated protein (anti-CarP) antibodies was significantly associated with a higher prevalence of bone erosions (OR 2.4) in patients with rheumatoid arthritis, independent of anti-CCP status.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: